We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Faced with growing pressure in Congress on the issue of drug prices, the new chairman of PhRMA has announced a three-point platform that includes greater price transparency as part of an effort to help Americans lower their healthcare costs without resorting to drug reimportation or price controls.
When traditional sales calls fail to achieve the desired results, or when reps find it difficult even to obtain a meeting with a physician, it may be time to change tactics and adopt alternative or complementary programs, according to two pharma marketing experts.
Pharmaceutical sales forces have expanded rapidly in recent years, but reductions in the time physicians are willing to spend with sales representatives combined with the increased risk of prosecution and civil litigation stemming from sales and marketing practices are making it difficult for drugmakers to balance rising sales expenses. If sales reps can’t meet with physicians or aren’t effective in promoting products, sales will suffer. If reps adopt tactics that violate false claims or antikickback statutes, legal costs and settlements can take a major bite out of earnings and subject the company to ongoing oversight and reporting requirements. This issue of FDL examines Rx sales training strategies to mitigate legal and regulatory compliance risk while turning challenges into opportunities to effectively communicate product benefits to physicians.
The Bush administration is proposing new international standards for fixed-dose combination AIDS drugs that could effectively bar generic drugmakers from participating in U.S. funded programs, some U.S. lawmakers and activists groups are charging.
The planned merger of Oriental Wave Holdings and Dragon Pharmaceutical could lead to the first Chinese firm being listed on Wall Street — evidence of China’s rise as a global player in the pharmaceutical industry, especially in the production of active pharmaceutical ingredients (APIs), analysts say.
Multiple generic firms started shipping versions of GlaxoSmithKline’s (GSK’s) antidepressant Wellbutrin SR (bupropion HCl extended- release) in 150-mg strength tablets last month after Andrx relinquished its 180-day exclusivity rights to the product.
Galen Holdings and Barr Pharmaceuticals have finalized deals that give Barr exclusive rights to Galen’s Loestrin oral contraceptive products and Galen the option to market Barr’s generic version of its own oral contraceptive Ovcon 35.
Despite unresolved patent issues, Teva Pharmaceutical on March 30 launched the first generic version of Purdue Pharma’s lucrative pain drug OxyContin (oxycodone) 80-mg strength extended-release tablets.